Video
Dr. Robert on Next Steps Following the Phase III COMBI-v Study in Melanoma
Author(s):
Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the next steps following the results of the phase III COMBI-v study in BRAF-mutant melanoma.
Caroline Robert, MD, PhD, Head of Dermatology, Institute Gustave-Roussy, discusses the next steps following the results of the phase III COMBI-v study in BRAF-mutant melanoma.
The study evaluated the efficacy of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) compared with vemurafenib (Zelboraf) monotherapy in patients with BRAF V600 mutation-positive advanced melanoma.
Next steps should focus on developing a better understanding of which subgroups of patients are responding best, and for the longest durations, says Robert. She also recommends a focus on more biomarker research, as well as an examination of potential combinations with immunotherapy that do not add too much toxicity.
